Patent · US Active

Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers

US8007995B2 · kind B2 · utility

12Cited by

20References

15Claims

0Family size

Assignees

Bristol-Myers Squibb Company · US
The Regents of the University of California · US

Inventors

Richard Finn · Calabasas, US
Judy Dering · Westlake Village, US
Dennis Slamon · Los Angeles, US
Charles L. Ginther · Los Angeles, US
Edwin Clark · Ashland, US

Key dates

Filing date	Nov 10, 2006
Grant date	Aug 30, 2011
Priority date	—
Expiry date	Apr 23, 2027

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/705
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.